MP28: Kidney Cancer: Advanced (including Drug Therapy) I

Poster Session Moderator(s)

• 

  Sarah Psutka, MD (she/her/hers)

  Associate Professor of Urology
  University of Washington, Fred Hutchinson Cancer Center
• 

  Yoshihiko Tomita, MD

  Niigata University

Presentations:

• 7:00 AM – 9:00 AM CST

  MP28-01: Cytoreductive Nephrectomy Perioperative Outcomes Have Significantly Improved in Recent Years
  

  Poster Presenter: Arighno Das, MD – University of Wisconsin
• 7:00 AM – 9:00 AM CST

  MP28-02: Consolidative Nephrectomy After Immunotherapy: Operative Characteristics and 90 Day Surgical Outcomes
  

  Poster Presenter: Stephen Reese, MD – Memorial Sloan Kettering Cancer Center
• 7:00 AM – 9:00 AM CST

  MP28-03: Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitors Is Safe and Facilitates Treatment Free Intervals
  

  Poster Presenter: Daniel Shapiro, MD (he/him/his) – University of Wisconsin School of Medicine and Public Health
• 7:00 AM – 9:00 AM CST

  MP28-04: Clinical and Immunogenomic Outcomes of Consolidative Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Treated with Immune Checkpoint Blockade
  

  Poster Presenter: Stephen Reese, MD – Memorial Sloan Kettering Cancer Center
• 7:00 AM – 9:00 AM CST

  MP28-05: The impact of metastasectomy on survival outcomes of renal cell carcinoma: a 10-year single center experience.
  

  Poster Presenter: Mariaconsiglia Ferriero, MD, PHD – "Regina Elena" National Cancer Institute
• 7:00 AM – 9:00 AM CST

  MP28-06: Clinical implications and predictive factors of primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
  

  Poster Presenter: Kazuyuki Numakura, MD – Akita University Graduate School of Medicine
• 7:00 AM – 9:00 AM CST

  MP28-07: The association of soluble PD-L1 and treatment response to nivolumab in patients with metastatic renal cell carcinoma
  

  Poster Presenter: Naoto Wakita, PhD (he/him/his) – Kobe University Graduate School of Medicine
• 7:00 AM – 9:00 AM CST

  MP28-08: Outcome change in patients with advanced renal cell carcinoma outside of clinical trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era
  

  Poster Presenter: Hiroki Ishihara, MD (he/him/his) – Tokyo Women's Medical University
• 7:00 AM – 9:00 AM CST

  MP28-09: Prognostic value of autologous cytokine-induced killer cells and dendritic cells (DC-CIKs) combination immunotherapy in patients with renal cell carcinoma
  

  Poster Presenter: Peng Ge, MD (he/him/his) – Affiliated Hospital of Xuzhou Medical University
• 7:00 AM – 9:00 AM CST

  MP28-10: Comparison of the Impacts of Immune-related Adverse Events on the Prognosis of Patients with Advanced Renal Cell Carcinoma between Patients Treated with IO-IO and IO-TKI Combination Therapy
  

  Poster Presenter: Hiroki Ishihara, MD (he/him/his) – Tokyo Women's Medical University
• 7:00 AM – 9:00 AM CST

  MP28-11: Long-term Prognosis and Risk Stratification for Adult MiT Family Translocation Renal Cell Carcinoma
  

  Poster Presenter: Jianzhong Shou, PhD
• 7:00 AM – 9:00 AM CST

  MP28-12: The impact of metastasis histopathology on survival for patients with advanced renal cell carcinoma
  

  Poster Presenter: Rodrigo R. Rodrigues Pessoa, MD,PhD
• 7:00 AM – 9:00 AM CST

  MP28-13: Peripheral fucosylated haptoglobin features predict durable responses to anti-PD-1 therapy in advanced renal cell carcinoma
  

  Poster Presenter: Taigo Kato, MD (he/him/his) – Osaka University Graduate School Of Medicine
• 7:00 AM – 9:00 AM CST

  MP28-14: Real-World Survival Outcomes Associated with Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Papillary Renal Cell Carcinoma
  

  Poster Presenter: Carlos Andres Riveros Sabogal, MD (he/him/his) – Houston Methodist Hospital
• 7:00 AM – 9:00 AM CST

  MP28-15: A new strategy to enhance cisplatin efficacy while reducing nephrotoxicity through targeted NEDDylation inhibition
  

  Poster Presenter: Kyle S. Garcia, MD
• 7:00 AM – 9:00 AM CST

  MP28-16: Generalizability of the MK-6482-004 trial to real-world VHL patients: results from a prospective surveillance study
  

  Poster Presenter: Federico Belladelli, MD – Ospedale San Raffaele
• 7:00 AM – 9:00 AM CST

  MP28-17: Role of adjuvant immunotherapy for patients with renal cell carcinoma at increased risk of recurrence following resection
  

  Poster Presenter: Harshit Garg, MD, M.Ch (he/him/his)
• 7:00 AM – 9:00 AM CST

  MP28-18: Adjuvant Immunotherapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
  

  Poster Presenter: Emily You Huang, MD (she/her/hers) – Houston Methodist Hospital
• 7:00 AM – 9:00 AM CST

  MP28-19: Patient perceptions of adjuvant therapy in renal cell carcinoma
  

  Poster Presenter: Michael D. Staehler, MD (he/him/his) – University of Munich
• 7:00 AM – 9:00 AM CST

  MP28-20: Robot-assisted radical nephrectomy and inferior vena cava level I-III thrombectomy: perioperative and mid-term oncologic outcomes
  

  Poster Presenter: Umberto Anceschi – IRCSS "regina Elena" National Cancer Institute